Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine-containing conditioning before allogeneic hematopoietic stem cell transplantation for high-risk MDS/AML
ChiCTR2000028993Phase 2Not yet recruiting
- Sponsor
- The Second Hospital of Hebei Medical University
- Start
- Jan 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by The Second Hospital of Hebei Medical University. Primary endpoints: Recurrence rate at 1 year after allo-HSCT, Overall survival rate at 1 year after allo-HSCT and 1 more. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2000028993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000028993.